Strategic Forecast for the Glioblastoma Multiforme (GBM) Treatment Industry: Market Outlook 2025-2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Glioblastoma Multiforme (GBM) Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for treating glioblastoma multiforme (GBM) has seen a swift expansion in the past few years. The market is projected to escalate from a value of $2.48 billion in 2024 to $2.74 billion in 2025, with a compound annual growth rate (CAGR) standing at 10.2%. Factors contributing to this significant growth during the historic period include a rise in incidence and prevalence, enhancement in diagnostic methods, intensified clinical trials and research funding, collaborations and partnerships, as well as an enriched comprehension of tumor biology.

Glioblastoma Multiforme (GBM) Treatment Market Size Forecast: What's the Projected Valuation by 2029?
The market size for glioblastoma multiforme (GBM) treatment is poised for swift expansion in the coming years, with expectations of growth to $4.1 billion in 2029, reflecting a compound annual growth rate (CAGR) of 10.6%. The growth during the forecast period can be credited to the emergence of immunotherapies, advancements in precision medicine, increasing knowledge of genetic markers, patient advocacy and awareness initiatives, along with government backing for rare diseases. Noteworthy trends predicted for this period encompass the exploration of combination therapies, utilization of artificial intelligence in diagnosis and treatment planning, increased acceptance of immunotherapeutic methods, and advanced medical tools and machinery.

View the full report here:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

What Are the Drivers Transforming the Glioblastoma Multiforme (GBM) Treatment Market?
Rise in the instances of brain disorders is anticipated to fuel the glioblastoma multiforme (GBM) treatment market's expansion. Brain disorders refer to the unusual activity of the brain and nerves that span the entire human body, including the spinal cord. The escalating rates of brain disorders such as glioblastoma multiforme (GBM) can be attributed to various factors such as an aging populace, weak immune systems, excessive diagnoses, ionizing radiation, air contamination, among others, which all necessitate the treatment for these brain conditions to enhance health and wellness. For instance, a study by the American Cancer Society-a US-based voluntary health organization focused on eradicating cancer-indicated that there were approximately 25,050 diagnosed cases of malignant tumors of the brain or spinal cord cancer in the US in the year 2022. Thus, the growing incidence of brain disorders is contributing to the growth of the glioblastoma multiforme (GBM) treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8803&type=smp

What Long-Term Trends Will Define the Future of the Glioblastoma Multiforme (GBM) Treatment Market?
Leading companies within the industry are concentrating on creating ground-breaking wearable and portable gadgets in order to retain their market status. This progress aims to provide users with augmented functionality, comfort, and ease of use, fulfilling the escalating requirement for effective and accessible healare resolutions. For example, in 2023, Novocure, an oncology firm based in Jersey, introduced Optune Gio, a wearable and transportable treatment appliance for patients newly diagnosed with glioblastoma (GBM), and was approved by the FDA. The device uses Tumor Treating Fields (TTFields), or alternating electric currents that disrupt the division of cancer cells, which could potentially extend the life expectancy of the patient. Weighing a mere 2.7 pounds, Optune Gio is designed with the patient's comfort in mind, making it possible for them to wear it while going about their daily routines.

Which Segments in the Glioblastoma Multiforme (GBM) Treatment Market Offer the Most Profit Potential?
The glioblastoma multiforme (GBM) treatment market covered in this report is segmented -

1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Surgery: Tumor Resection, Biopsy Procedures
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens
4) By Targeted Therapy: EGFR Inhibitors, Other Targeted Agents
5) By Tumor Treating Field (TTF) Therapy: Device-Based TTF Treatment
6) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8803&type=smp

Which Firms Dominate the Glioblastoma Multiforme (GBM) Treatment Market by Market Share and Revenue in 2025?
Major companies operating in the glioblastoma multiforme (GBM) treatment market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, ANI Pharmaceuticals Inc., Accord Healare Limited, The Eckert & Ziegler Group, Loxo Oncology Inc., Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., EnGeneIC Ltd., Zydus Pharmaceuticals Inc., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.

Which Regions Offer the Highest Growth Potential in the Glioblastoma Multiforme (GBM) Treatment Market?
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8803

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.